ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous select...
Q1 2026
May 15, 2026
FY 2025
Mar 18, 2026
Q4 2025
Q3 2025
Nov 10, 2025
Q2 2025
Aug 12, 2025